Detection, control, and management of a respiratory syncytial virus outbreak in a pediatric hematology-oncology department

Journal of Pediatric Hematology/Oncology

Volumn 35, Issue 2, 2013, Pages 124-128

  Shachor Meyouhas, Yael ^a   Zaidman, Irina ^a   Kra Oz, Zipi ^a   Arad Cohen, Nira ^a   Kassis, Imad ^a  

^a MEYER CHILDREN S HOSPITAL   (Israel)

Author keywords

infections in immunocompromised hosts; outbreak; respiratory syncytial virus

Indexed keywords

AMIKACIN; PALIVIZUMAB; PIPERACILLIN PLUS TAZOBACTAM;

ABSENCE OF SIDE EFFECTS; ARTICLE; CANCER PATIENT; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; EPIDEMIC; FEVER; HUMAN; INFANT; INFECTION CONTROL; LUNG INJURY; NEUTROPENIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY FAILURE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SINGLE DRUG DOSE; THORAX RADIOGRAPHY; TREATMENT RESPONSE; VIRUS DETECTION;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; HEMATOLOGIC NEOPLASMS; HUMANS; INFANT; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY TRACT INFECTIONS;

EID: 84874466500     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3182756edc     Document Type: Article

References (20)

1. Miron D, Srugo I, Kra-Oz Z, et al. Sole pathogen in acute bronchiolitis: is there a role for other organisms apart from respiratory syncytial virus? Pediatr Infect Dis J. 2010;29:e7-e10.
2. Kassis I, Srugo I, Srur S, et al. The burden and outcomes of acute bronchiolitis among young children hospitalized in Israel. Harefuah. 2009;148:748-751.
3. Chavez-Bueno S, Mejias A, Merryman RA, et al. Intravenous palivizumab and ribavirin combination for respiratory syncy-tial virus disease in high-risk pediatric patients. Pediatr Infect Dis J. 2007;26:1089-1093.
4. El Saleeby CM, Somes GW, DeVincenzo JP, et al. Risk factors for severe respiratory syncytial virus disease in children with cancer: the importance of lymphopenia and young age. Pediatrics. 2008;121:235-243.
5. Sung L, Alonzo TA, Gerbing RB, et al. Children's Oncology Group. Respiratory syncytial virus infections in children with acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2008;51:784-786.
6. Khanna N, Widmer AF, Decker M, et al. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis. 2008;46:402-412.
7. Anak S, Atay D, Unuvar A, et al. Respiratory syncytial virus infection outbreak among pediatric patients with oncologic diseases and/or BMT. Pediatr Pulmonol. 2010;45: 307-311.
8. Kassis C, Champlin RE, Hachem RY, et al. Detection and control of a nosocomial respiratory syncytial virus outbreak in a stem cell transplantation unit: the role of palivizumab. Biol Blood Marrow Transplant. 2010;16:1265-1271.
9. Whimbey E, Champlin RE, Couch RB, et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis. 1996;22:778-782.
10. Whimbey E, Champlin RE, Englund JA, et al. Combination therapy with aerosolized ribavirin and intravenous immuno-globulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant. 1995;16:393-399.
11. Harrington RD, Hooton TM, Hackman RC, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis. 1992;165:987-993.
12. Adams RH. Preemptive treatment of pediatric bone marrow transplant patients with asymptomatic respiratory syncytial virus infection with aerosolized ribavirin. Biol Blood Marrow Transplant. 2001;7:16s-18s.
13. de Fontbrune FS, Robin M, Porcher R, et al. Palivizumab treatment of respiratory syncytial virus infection after alloge-neic hematopoietic stem cell transplantation. Clin Infect Dis. 2007;45:1019-1024.
14. Boeckh M, Berry MM, Bowden RA, et al. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis. 2001;184:350-354.
15. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15:1143-1238.
16. Madge P, Paton JY, McColl JH, et al. Prospective controlled study to prevent nosocomial infection with respiratory syncytial virus. Lancet. 1992;340:1079-1083.
17. Empey KM, Peebles RS Jr, Kolls JK. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin Infect Dis. 2010;50:1258-1267.
18. Johnson S, Oliver C, Prince GA, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997;176:1215-1224.
19. Johnson S, Griego SD, Pfarr DS, et al. A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9. J Infect Dis. 1999;180:35-40.
20. Saez-Llorens X, Moreno MT, Ramilo O, et al. MEDI-493 Study Group. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J. 2004;23:707-712.